United States: FDA Policy Aims To Smooth Generic Access To Samples Of Branded Drugs Subject To REMS Use Restrictions

In a draft guidance published December 4, 2014,1 the Food and Drug Administration (FDA) has attempted to remove, at least in part, a legal hurdle that had created challenges for generic drug companies: Acquiring the samples of brand name products required to perform the bioequivalence studies that are the linchpin to the generic drug approval process, as well as other analytical comparisons required for submission and approval of an Abbreviated New Drug Application (ANDA).

Background on REMS Programs and Their Impact on Generic Access to Innovator Product Samples

FDA long has recognized that some drugs that pose significant benefit/risk issues that might otherwise keep them from being approved could come to the market if additional measures beyond those provided in the product labeling were implemented relative to the drug posing the questionable benefit/risk ratio. Thus, with drugs such as Accutane® and Thalomid®, both of which can cause birth defects, the agency and the drugs' sponsors entered into arrangements where, as a condition of approval, the sponsors agreed to certain measures such as requiring women of childbearing years to agree to a pregnancy test before initiating treatment and to use birth control while taking the drugs.

Initially, these arrangements were not formally authorized by the Federal Food, Drug, and Cosmetic Act (FFDCA), but the sponsors agreed to the risk management provisions in order to secure approval. In 2007, Congress passed the Food and Drug Administration Amendments Act (the 2007 Amendments),2 which formally gave FDA the power to require innovative drug sponsors to initiate such programs – called Risk Evaluation and Mitigation Strategies (REMS) when the agency believed the risk/benefit ratio required such measures.

While many common REMS measures, such as medication guides and communication plans, do not directly impede access to the drug, the 2007 Amendments also gave FDA the power to require, in appropriate circumstances, that the innovator implement certain Elements To Assure Safe Use (ETASU)—such as the pregnancy test and contraception requirements already in place for Accutane®—for drugs that posed, in the agency's view, great enough risks that other measures were inadequate to ensure that the products could be safely used. In conjunction with giving FDA the power to require an ETASU, the 2007 Amendments also amended the FFDCA to render as misbranded any drug that was in violation of a REMS program measure such as ETASU requirements.3

An unintended consequence of approving a new drug application (NDA) for a drug with an ETASU program has been that, in many cases, generic firms seeking to acquire the samples of the NDA product found themselves unable to acquire the products from the holder of the NDA due to the ETASU restrictions. When pushed by generic firms to make samples of drugs subject to an ETASU available, holders of the approval for the brand NDA – referred to in the generic drug approval process as the "reference listed drug" (RLD) – have cited a number of grounds for why they should not be required to provide the samples to the generics, especially falling back on the assertion that they cannot legally provide the product under the REMS misbranding provisions of the FFDCA. Innovators also claimed that state tort law/products liability considerations also would expose them to liability by providing the samples to generic companies.

What the Draft Guidance Provides

In the draft guidance issued December 4, FDA created a mechanism for generic firms to request that FDA send a letter to the RLD holder of a drug subject to an ETASU. Before the letter can be sent to the RLD NDA holder, a generic firm will have to submit its bioequivalence protocol—including informed consent documents and other "informational materials"—reflecting the required ETASU elements to the agency for review. If FDA agrees that the protocol does contain the required ETASU measures, the generic firm will also have to provide FDA with a completed "disclosure authorization form" before FDA can issue the letter to the RLD holder.

In the letter to the RLD holder, FDA would inform the firm that the agency would not regard the innovator's provision of the samples of the RLD to the generic as a "violation of REMS." Specifically, the letter would state:

The Agency has determined that the protocols, informed consent documents, and informational materials contain safety protections comparable to those in the applicable REMS ETASU.

FDA will not consider it a violation of REMS for the RLD sponsor to provide the designated potential ANDA applicant (or its agent) a sufficient quantity of drug product to allow it to perform the testing necessary to support its ANDA and otherwise meet the requirements for ANDA approval.4

The guidance does not say how quickly FDA will respond to ANDA applicant requests for letters to the RLD holder of ETASU-restricted drugs. However, as the agency has a commitment to trying to secure the approval of "first generics" of previously sole source brand name products, FDA is likely to move fairly quickly on any requests made under the draft guidance.

Will the Draft Guidance Really Generate Access to Innovator Samples Subject to ETASU?

While the draft guidance would appear to remove one crucial element of innovator resistance to providing samples of the RLD to generic firms where an ETASU is in place, we expect that RLD holders will continue to resist making these products available. Indeed, several issues are not addressed by the draft guidance.

First, from an administrative law perspective, the draft guidance, even if it was in final form, would not have the force and effect of a law, as it is neither a regulation nor a statute. FDA makes clear that guidance documents are neither binding on FDA nor on industry. In addition, the guidance expresses, as a matter of policy, FDA's decision to, in effect, exercise its "enforcement discretion" to not hold an innovator company in violation of the law if it distributes a product in a manner that is not fully consistent with an ETASU in order to make samples available to a generic firm. We expect that some innovators may assert that they still would be technically in violation of the FFDCA by deviating from a REMS program and decline to make samples available under that rationale.

In addition, the draft guidance does not compel an innovator to provide the generic with samples. To date, this issue, which includes a focus on the non-FDA legal issue of whether a person can decline to do business with another person, has been the subject of litigation in several federal district courts. However, none of those lawsuits has resulted in a decision with any precedential value.

Finally, innovator companies contend that, even with FDA's blessing as reflected in the draft guidance, the innovators would expose themselves to liability under various state products liability and tort principles if they were to provide samples of a drug subject to an ETASU to a generic firm. While a generic firm could agree to indemnify and hold harmless an innovator under such circumstances, absent a court finding that the innovator must deal with the generic and provide samples, we would expect that innovators continue to decline to make samples available for as long as they can continue to assert a colorable argument from both a legal and policy perspective that they are not required to share their product with the generic industry.

Congress may eventually have to weigh in on this issue. Indeed, in September 2014, H.R. 5657, the Fair Access for Safety and Timely (FAST) Generics Act,5 was introduced by Reps. Steve Stivers (R-Ohio) and Peter Welch (D-Vt.). If enacted, the FAST Generics Act, among other things, actually would render misbranded any drug subject to a REMS if the NDA holder failed to supply samples of REMS-restricted RLD to an ANDA applicant or an applicant seeking to approval of a biosimilar under the Biosimilar Price Competition and Innovation Act of 2009. While it appears to enjoy bipartisan support, it remains to be seen how fast the FAST Generics Act moves through the halls of Congress.

If you have any questions about this Alert, please contact Frederick (Rick) R. Ball, Michael A. Swit, any member of the Pharmaceutical, Medical Device, Pharmacy and Food industry group or the attorney in the firm with whom you are regularly in contact.


1. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425662.pdf.

2. Public Law 110-85 (September 27, 2007).

3. Section 502(y) of the FFDCA; codified at 21 USC § 352(y).

4. Draft Guidance, at 4.

5. See HR 5657, at https://www.congress.gov/bill/113th-congress/house-bill/5657/text.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.